Biotech Market Research – Different Approach To Stay Ahead Of Your Competitor

Ehlers-Danlos Syndrome Market Ehlers-Danlos syndrome (EDS) is a disease that weakens the connective tissues of your body. These are things like tendons and ligaments that hold parts of your body together. EDS can make your joints loose and your skin thin and easily bruised. It also can weaken blood vessels and organs. Some facts of Ehlers-Danlos Syndrome Market Report are: ·          The combined prevalence of all types of Ehlers-Danlos syndrome appears to be  at least 1 in 5,000 individuals worldwide. ·          Vascular EDS is reported to have a prevalence of 1 in 100,000 individuals, and cardiac-valvular EDS a prevalence of less than 1 in a million people. ·          The estimated prevalence for all EDS varies between 1/10,000 and 1/25,000, EDS type IV representing approximately 5 to 10% of cases. View Report: https://www.delveinsight.com/report-store/ehlers-danlos-syndrome-market Some of Ehlers-Danlos Syndrome Companies are: ·          Aventis Pharmaceuticals ·

Chondrosarcoma Market Chondrosarcoma is a bone sarcoma that develops in the cartilage cells. It mostly affects adults above the age of 40 and the most common sites are the upper arm, pelvis and thigh bone. Chondrosarcomas can be subdivided in several ways: by histologic grade, whether they arise de novo (primary) or from benign lesions (secondary), by location within the bone (central or peripheral), or by syndrome. Some of the facts: ·          According to the US Surveillance, Epidemiology and End Results Program, Chondrosarcomas contribute 30% among different types of bone cancer. ·          Chondrosarcomas develops most often in adults, with an average age at diagnosis of 51. Less than 5% of cases occur in patients younger than 20. ·          Chondrosarcoma is a tumor of adulthood and older age. The majority of patients are older than 50 years of age at diagnosis, with a slight male predominance. ·          Chondrosarcomas are sporadic, but they may develop from the ma